



2 0 1 6  
**9<sup>th</sup>** PARIS  
HEPATITIS  
CONFERENCE

**Organised by Pr Patrick Marcellin**

**Organising Committee:**

Emilie Estrabaud, Michelle Martinot-Peignoux  
Monelle Muntlak

Hôpital Beaujon, APHP - INSERM CRI - Université Paris-Diderot

**Scientific Committee:**

Marc Bourlière, Massimo Colombo,  
Rafael Esteban, Graham Foster,  
Michael Fried, Michael Manns

**11<sup>th</sup> & 12<sup>th</sup> January 2016**  
**PARIS** - Palais des Congrès

[www.aphc.info](http://www.aphc.info)



*Follow us on Twitter:*

*@PHC\_off #PHC2016*





**Patrick MARCELLIN**

PRESIDENT OF PHC

*Happy New Year!*

11<sup>th</sup> & 12<sup>th</sup> January 2016 / PARIS - Palais des Congrès

# Welcome and thanks to 1000 participants from 75 countries !

Albania  
Algeria  
Argentina  
Armenia  
Austria  
Azerbaijan  
Belgium  
Benin  
Brazil  
Bulgaria  
Cameroon  
Canada  
China  
Colombia  
Cote Divoire  
Croatia  
Czech Republic  
Denmark  
Dominican Republic  
Egypt  
Finland  
France  
Gabon  
Georgia  
Germany

Greece  
Guadeloupe  
Guyana  
Haiti  
Hong Kong  
Hungary  
India  
Indonesia  
Iraq  
Ireland  
Italy  
Korea Sout  
Kuwait  
Latvia  
Lebanon  
Libya  
Lithuania  
Luxembourg  
Madagascar  
Malta  
Mexico  
Mongolia  
Morocco  
Mozambique  
Nambia

Netherlands  
Nigeria  
Norway  
Oman  
Peru  
Poland  
Portugal  
Reunion  
Romania  
Russia  
Saudi Arabia  
Senegal  
Seychelles  
Slovakia  
Slovenia  
Spain  
Sweden  
Switzerland  
Taiwan  
Tunisia  
Turkey  
Ukraine  
United Arab Em.  
United Kingdom  
USA

# 9th PHC: Faculty Members

Nezam AFDHAL  
Tarik ASSELAH  
Pierre BEDOSSA  
Najet BELHADJ BRIK  
Mustapha BENAZZOUZ  
Marc BOURLIERE  
Jean-Pierre BRONOWICKI  
Savino BRUNO  
Maria BUTI  
Jean-François CADRANEL  
Laurent CASTERA  
Massimo COLOMBO  
Antonio CRAXI  
Victor DE LEDINGHEN  
Nabil DEBZI  
Daniel DHUMEAUX  
Adrian DI BISCEGLIE  
Vincent DI MARTINO  
François DURAND  
Ahmed EI RAY  
Gamal ESMAT  
Rafael ESTEBAN  
Emilie ESTRABAUD  
Peter FERENCI  
Robert FLISIAK  
Graham FOSTER

Claire FRANCOZ  
Michael FRIED  
Adrian GADANO  
Pere GINES  
Jérôme GOURNAY  
Philippe HALFON  
Christophe HEZODE  
Andrzej HORBAN  
Vasily ISAKOV  
Ji Dong JIA  
Jia-Horng KAO  
Pietro LAMPERTICO  
Vincent LEROY  
Massimo LEVRERO  
Jake LIANG  
Michael MANNS  
Patrick MARCELLIN  
Michelle MARTINOT-PEIGNOUX  
Philippe MATHURIN  
Richard MOREAU  
Rami MOUCARI  
David NELSON  
Denis OUZAN  
Georges-Philippe PAGEAUX  
Raluca PAIS  
Georgios PAPTAEODORIDIS

Raymundo PARANA  
Jean-Marie PÉRON  
Antonello PIETRANGELO  
Stanislas POL  
Adriana POPESCU  
Vlad RATZIU  
Mario RIZZETTO  
Dominique SALMON  
Didier SAMUEL  
Eugene SCHIFF  
Lawrence SERFATY  
Mitchell SHIFFMAN  
Philippe SOGNI  
Mark SULKOWSKI  
Tengiz TSERTSVADZE  
Albert TRAN  
Christian TREPO  
Petr URBANEK  
Dominique VALLA  
Mihai VOICULESCU  
Imam WAKED  
Yazdan YAZDANPANAH  
Jean-Pierre ZARSKI  
Stefan ZEUZEM  
Konstantin ZHDANOV  
Fabien ZOULIM

# 9th PHC: Scientific Committee

Marc BOURLIERE (France)

Massimo COLOMBO (Italy)

Rafael ESTEBAN (Spain)

Graham FOSTER (UK)

Michael FRIED (USA)

Michael MANNS (Germany)

# We have the weapons against HCV we dreamed of!

## Confirmed in real life studies...



100% efficacy



All oral



Short duration



No resistance




Pan-genotypic




Well tolerated and safe

Cost...

# Amazing acceleration of progress in the last years



Most of patients around the world have  
no access to DAAs

A world map is shown in a dark blue color. A semi-transparent blue rectangular box is overlaid on the map, centered over the Atlantic Ocean. Inside this box, the text "170 million HCV patients" is written in white. The map highlights several regions in a lighter blue color, including North America, South America, Europe, and parts of Africa and Asia.


170 million  
HCV patients



A world map is shown in the background, with the continents of North America, Europe, and Asia highlighted in a bright yellow color. The rest of the map is in a dark blue color. A dark blue rectangular box is overlaid on the map, containing white text.

Majority of  
patients treated  
with IFN/RBV

# Restricted indications of DAAs in Europe





How to improve access  
to therapy?



**Enjoy your PHC meeting!**

**11<sup>th</sup> & 12<sup>th</sup> January 2016 / PARIS - Palais des Congrès**

# State of the Art Lecture

*Chairman : Tarik ASSELAH*

**The influence of therapy on the burden of hepatitis**

*Michael FRIED*

**9th PHC:**